Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study
Abstract Background and Aim Understanding the prevalence and impact of SARS‐CoV‐2 variants has assumed paramount importance. This study statistically analyzed to effectively track the emergence and spread of the variants and highlights the importance of such investigations in developing potential ne...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-10-01
|
| Series: | Health Science Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/hsr2.1596 |
| _version_ | 1827350918437273600 |
|---|---|
| author | Ranjan K. Mohapatra Snehasish Mishra Venkataramana Kandi Francesco Branda Azaj Ansari Ali A. Rabaan Md. Kudrat‐E‐Zahan |
| author_facet | Ranjan K. Mohapatra Snehasish Mishra Venkataramana Kandi Francesco Branda Azaj Ansari Ali A. Rabaan Md. Kudrat‐E‐Zahan |
| author_sort | Ranjan K. Mohapatra |
| collection | DOAJ |
| description | Abstract Background and Aim Understanding the prevalence and impact of SARS‐CoV‐2 variants has assumed paramount importance. This study statistically analyzed to effectively track the emergence and spread of the variants and highlights the importance of such investigations in developing potential next‐gen vaccine to combat the continuously emerging Omicron subvariants. Methods Transmission fitness advantage and effective reproductive number (Re) of epidemiologically relevant SARS‐CoV‐2 sublineages through time during the study period based on the GISAID data were estimated. Results The analyses covered the period from January to June 2023 around an array of sequenced samples. The dominance of the XBB variant strain, accounting for approximately 57.63% of the cases, was identified during the timeframe. XBB.1.5 exhibited 37.95% prevalence rate from March to June 2023. Multiple variants showed considerable global influence throughout the study, as sporadically documented. Notably, the XBB variant demonstrated an estimated relative 28% weekly growth advantage compared with others. Numerous variants were resistant to the over‐the‐counter vaccines and breakthrough infections were reported. Similarly, the efficacy of mAB‐based therapy appeared limited. However, it's important to underscore the perceived benefits of these preventive and therapeutic measures were restricted to specific variants. Conclusion Given the observed trends, a comprehensive next‐gen vaccine coupled with an advanced vaccination strategy could be a potential panacea in the fight against the pandemic. The findings suggest that targeted vaccine development could be an effective strategy to prevent infections. The study also highlights the need of global collaborations to rapidly develop and distribute the vaccines to ensure global human health. |
| first_indexed | 2024-03-08T01:44:45Z |
| format | Article |
| id | doaj.art-e7701f244b7c4898852c0c6caa9d29e6 |
| institution | Directory Open Access Journal |
| issn | 2398-8835 |
| language | English |
| last_indexed | 2024-03-08T01:44:45Z |
| publishDate | 2023-10-01 |
| publisher | Wiley |
| record_format | Article |
| series | Health Science Reports |
| spelling | doaj.art-e7701f244b7c4898852c0c6caa9d29e62024-02-14T13:06:23ZengWileyHealth Science Reports2398-88352023-10-01610n/an/a10.1002/hsr2.1596Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational studyRanjan K. Mohapatra0Snehasish Mishra1Venkataramana Kandi2Francesco Branda3Azaj Ansari4Ali A. Rabaan5Md. Kudrat‐E‐Zahan6Department of Chemistry Government College of Engineering Keonjhar Odisha IndiaSchool of Biotechnology, Campus‐11 KIIT Deemed‐to‐be‐University Bhubaneswar Odisha IndiaDepartment of Microbiology Prathima Institute of Medical Sciences Karimnagar Telangana IndiaDepartment of Computer Science, Modeling, Electronics and Systems Engineering (DIMES) University of Calabria Rende ItalyDepartment of Chemistry Central University of Haryana Mahendergarh Haryana IndiaMolecular Diagnostic Laboratory Johns Hopkins Aramco Healthcare Dhahran Saudi ArabiaDepartment of Chemistry Rajshahi University Rajshahi BangladeshAbstract Background and Aim Understanding the prevalence and impact of SARS‐CoV‐2 variants has assumed paramount importance. This study statistically analyzed to effectively track the emergence and spread of the variants and highlights the importance of such investigations in developing potential next‐gen vaccine to combat the continuously emerging Omicron subvariants. Methods Transmission fitness advantage and effective reproductive number (Re) of epidemiologically relevant SARS‐CoV‐2 sublineages through time during the study period based on the GISAID data were estimated. Results The analyses covered the period from January to June 2023 around an array of sequenced samples. The dominance of the XBB variant strain, accounting for approximately 57.63% of the cases, was identified during the timeframe. XBB.1.5 exhibited 37.95% prevalence rate from March to June 2023. Multiple variants showed considerable global influence throughout the study, as sporadically documented. Notably, the XBB variant demonstrated an estimated relative 28% weekly growth advantage compared with others. Numerous variants were resistant to the over‐the‐counter vaccines and breakthrough infections were reported. Similarly, the efficacy of mAB‐based therapy appeared limited. However, it's important to underscore the perceived benefits of these preventive and therapeutic measures were restricted to specific variants. Conclusion Given the observed trends, a comprehensive next‐gen vaccine coupled with an advanced vaccination strategy could be a potential panacea in the fight against the pandemic. The findings suggest that targeted vaccine development could be an effective strategy to prevent infections. The study also highlights the need of global collaborations to rapidly develop and distribute the vaccines to ensure global human health.https://doi.org/10.1002/hsr2.1596COVID‐19next‐gen vaccineOmicron variantspandemic trackingSARS‐CoV‐2 variantvaccine efficacy |
| spellingShingle | Ranjan K. Mohapatra Snehasish Mishra Venkataramana Kandi Francesco Branda Azaj Ansari Ali A. Rabaan Md. Kudrat‐E‐Zahan Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study Health Science Reports COVID‐19 next‐gen vaccine Omicron variants pandemic tracking SARS‐CoV‐2 variant vaccine efficacy |
| title | Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study |
| title_full | Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study |
| title_fullStr | Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study |
| title_full_unstemmed | Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study |
| title_short | Analyzing the emerging patterns of SARS‐CoV‐2 Omicron subvariants for the development of next‐gen vaccine: An observational study |
| title_sort | analyzing the emerging patterns of sars cov 2 omicron subvariants for the development of next gen vaccine an observational study |
| topic | COVID‐19 next‐gen vaccine Omicron variants pandemic tracking SARS‐CoV‐2 variant vaccine efficacy |
| url | https://doi.org/10.1002/hsr2.1596 |
| work_keys_str_mv | AT ranjankmohapatra analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy AT snehasishmishra analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy AT venkataramanakandi analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy AT francescobranda analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy AT azajansari analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy AT aliarabaan analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy AT mdkudratezahan analyzingtheemergingpatternsofsarscov2omicronsubvariantsforthedevelopmentofnextgenvaccineanobservationalstudy |